Studies in mice have suggested a role for IL-22 in MetS and T2D treatment, as IL-22 administration resulted in improved glycaemic control, insulin sensitivity, and lipid metabolism, concomitantly with improved intestinal barrier function and reduced inflammation [1,3,9,10,11]. This evidence concerns the gene IL22 and type 2 diabetes mellitus.